参松养心胶囊治疗脑心综合征的临床观察

目的观察参松养心胶囊治疗脑心综合征的f临床疗效和不良反应。方法160例脑心综合征患者随机分为2组：对照组80例，治疗组80例。对照组给予常规治疗，治疗组在常规治疗基础上加服参松养心胶囊，每次4粒，每天3次，疗程均4周，观察临床疗效和不良反应。结果治疗组总有效率为90.0％高于对照组的76.3％，差异有统计学意义（P〈0.01），且无明显不良反应。2组治疗后心电图（心律失常、ST-T改变）、心肌酶改变比较差异有统计学意义（P〈0.05）。结论参松养心胶囊治疗脑心综合征有良好疗效，且不良反应小。

Clinical study of Shensongyangxin Capsule in the treatment of patients with cerebrocardiac syndrome

Objective To observe the clinical therapeutic efficacy of Shensongyangxin Capsule on cerebrocardiac syndrome. Methods 160 patients with cerebrocardiac syndrome were randomly divided into treatment group （n=80） and control group （n=80）. The patients in control group were treated with routine western medicine, while the patients in treatment group, on the basis of routine therapy, were treated with Shensongyangxin capsule,4 capsules once,3 time a day ,and the treatment course was 4 weeks for beth groups. After one treatment course, the clinical efficacy and adverse reactions were compared be-tween two groups. Results The total effective rates in treatment group and control group were 90.0% and 76.3% respectively, there was a significant difference between two groups （P〈0.01）. The effective rate in treatment group was better than that in control group. There were few adverse reactions in the treatment group. After treatment, ariythmia, ST-T and myocardium enzyme were greatly improved , there were significant difference between two groups （P 〈 0.05）. Conclusion Shensongyangxin capsule has good clinical curative in treating cerebrocardiac syndrome.